Unknown

Dataset Information

0

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.


ABSTRACT: BACKGROUND:Androgen deprivation therapy (ADT) remains the standard therapy for patients with oligometastatic prostate cancer (OMPC). Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT)-based stereotactic body radiotherapy (SBRT) is emerging as an alternative option to postpone starting ADT and its associated side effects including the development of drug resistance. The aim of this study was to determine progression free-survival (PFS) and treatment failure free-survival (TFFS) after PSMA-PET/CT-based SBRT in OMPC patients. The efficacy and safety of single fraction radiosurgery (SFRS) and ADT delay were investigated. METHODS:Patients with ?5 metastases from OMPC, with/without ADT treated with PSMA-PET/CT-based SBRT were retrospectively analyzed. PFS and TFFS were primary endpoints. Secondary endpoints were local control (LC), overall survival (OS) and ADT-free survival (ADTFS). RESULTS:Fifty patients with a total of 75 metastases detected by PSMA-PET/CT were analyzed. At the time of SBRT, 70% of patients were castration-sensitive. Overall, 80% of metastases were treated with SFRS (median dose 20 Gy, range: 16-25). After median follow-up of 34 months (range: 5-70) median PFS and TFFS were 12 months (range: 2-63) and 14 months (range: 2-70), respectively. Thirty-two (64%) patients had repeat oligometastatic disease. Twenty-four (48%) patients with progression underwent second SBRT course. Two-year LC after SFRS was 96%. Grade 1 and 2 toxicity occurred in 3 (6%) and 1 (2%) patients, respectively. ADTFS and OS rates at 2-years were 60.5% and 100%, respectively. In multivariate analysis, TFFS significantly improved in patients with time to first metastasis (TTM) >36 months (p = 0.01) and PSA before SBRT ?1 ng/ml (p = 0.03). CONCLUSION:For patients with OMPC, SBRT might be used as an alternative to ADT. This way, the start/escalation of palliative ADT and its side effects can be deferred. Metastases treated with PSMA-PET/CT-based SFRS reached excellent LC with minimal toxicity. Low PSA levels and longer TTM predict elongated TFFS.

SUBMITTER: Kalinauskaite G 

PROVIDER: S-EPMC7577453 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.

Kalinauskaite Goda G   Senger Carolin C   Kluge Anne A   Furth Christian C   Kufeld Markus M   Tinhofer Ingeborg I   Budach Volker V   Beck Marcus M   Hochreiter Alexandra A   Grün Arne A   Stromberger Carmen C  

PloS one 20201021 10


<h4>Background</h4>Androgen deprivation therapy (ADT) remains the standard therapy for patients with oligometastatic prostate cancer (OMPC). Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT)-based stereotactic body radiotherapy (SBRT) is emerging as an alternative option to postpone starting ADT and its associated side effects including the development of drug resistance. The aim of this study was to determine progression free-survival (PFS) and tr  ...[more]

Similar Datasets

| S-EPMC7761444 | biostudies-literature
| S-EPMC6885020 | biostudies-literature
| S-EPMC4066290 | biostudies-literature
| S-EPMC6352289 | biostudies-literature
| S-EPMC6868044 | biostudies-literature
| S-EPMC8089391 | biostudies-literature
| S-EPMC10461474 | biostudies-literature
| S-EPMC5355341 | biostudies-literature
| S-EPMC8517476 | biostudies-literature